3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
NET
1
Endocrine
1
CNS
1
Conditions
Ovarian Neoplasms
86
Breast Neoplasms
68
Triple Negative Breast Neoplasms
32
Prostatic Neoplasms
32
Fallopian Tube Neoplasms
25
Neoplasms
23
Neoplasm Metastasis
21
Pancreatic Neoplasms
18
Endometrial Neoplasms
18
Small Cell Lung Carcinoma
13
Carcinoma, Ovarian Epithelial
11
Carcinoma, Non-Small-Cell Lung
10
Stomach Neoplasms
9
Sarcoma
9
Recurrence
9
Lung Neoplasms
9
Fanconi Anemia, Complementation Group D1
9
Squamous Cell Carcinoma of Head and Neck
8
Glioma
8
Parkinson Disease 4, Autosomal Dominant Lewy Body
7
Glioblastoma
7
Colorectal Neoplasms
6
Metastatic Castration-resistant Prostate Cancer
5
Lymphoma, Non-Hodgkin
5
Cholangiocarcinoma
5
Carcinoma, Renal Cell
5
Uterine Cervical Neoplasms
4
Urinary Bladder Neoplasms
4
Solid Tumors
4
Osteosarcoma
4
Interventions
Adrenalectomy
3
Radiosurgery
2
Nivolumab
2
Magnetic Resonance Spectroscopy
2
Fluorodeoxyglucose F18
2
FAPI-46
2
pertuzumab
1
olaparib
1
lutetium Lu 177 dotatate
1
iodophenyl metomidate
1
camrelizumab
1
apatinib
1
X-Rays
1
Radiofrequency Ablation
1
Observation
1
Nephrectomy
1
N-(2,6-bis(1-methylethyl)phenyl)-N'-((1-(4-(dimethylamino)phenyl)cyclopentyl)methyl)urea hydrochloride
1
Mitotane
1
Gefitinib
1
Floxuridine
1
Erlotinib Hydrochloride
1
Dexamethasone
1
Cystectomy
1
Cryosurgery
1
Adosterol
1
(18F)GTP1
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Adrenal Gland Neoplasms
×
olaparib
×
Clear all
NCT06607692
2026-06-04
LUPARPED
Fundación de investigación HM
Phase 1/2
Recruiting
25 enrolled